Sign in
Taking people in United StatesPhase 1/2

Tests surovatamig alone or with other drugs in B-cell blood cancers

Tests surovatamig, alone or combined, in adults with B-cell blood cancers.

Key facts

Who runs it
AstraZeneca
Where
Boston, Charlotte, Columbus, Hackensack, Houston, New Brunswick, New York, Philadelphia, Pittsburgh, Portland, Providence, and Winston-Salem, United StatesSee the 12 sitesAlso in 12 other countries, 47 sites
Registry title
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Status
Recruiting
Phase
Phase 1/2
People taking part
408 people, planned
Started
30 Jan 2025
Expected to end
20 May 2030
Type of study
Interventional, 7 groups
Treatments tested
  • Surovatamig
  • Prednisone (or equivalent)
  • Rituximab
  • Cyclophosphamide
  • Vincristine
  • Doxorubicin
  • Acalabrutinib
Record updated
28 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with certain B-cell blood cancers or lymphomas: CLL/SLL, mantle cell lymphoma or large B-cell lymphoma. They are treated with surovatamig alone or with other cancer drugs.

Age
18 years or older. In the large B-cell lymphoma part, no older than 79 years.
Sex
All sexes can join.
Disease stage
CLL/SLL part: CLL needing treatment, or SLL with at least 1 measurable site. Mantle cell lymphoma part: Stage II, III or IV. Large B-cell lymphoma part: at least 1 measurable site and an IPI score of 2 to 5.
Earlier treatment
CLL/SLL: at least 2 prior lines of treatment in cohorts 1A and 1C, at least 1 in cohort 1B (BTK inhibitor-sensitive). Mantle cell lymphoma: 2 or more lines including a BTK inhibitor in cohorts 2A and 2C. Large B-cell lymphoma: no earlier treatment in cohort 3B; cohort 3A is untreated or relapsed after at least 1 prior line.
Biomarker or test result
CD19 expression must be confirmed if the person had earlier anti-CD19 treatment.

Main reasons for not taking part

  • Lymphoma in the central nervous system
  • Earlier CAR T-cell therapy or T-cell engager treatment within the set time windows
  • Earlier severe cytokine release syndrome or neurotoxicity (Grade > 3)
  • Active, significant, uncontrolled infection or autoimmune disease needing systemic treatment
  • Clinically significant heart disease

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • Master Inclusion Criteria applicable to all substudies:
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Contraception use during treatment and at least 90 days after final dose
  • Confirmed CD19 expression if prior anti-CD19 therapy; Substudy 1 Specific Inclusion Criteria:
  • Participants with CLL must require treatment according to the international workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria
  • SLL: at least 1 measurable site per Lugano
  • Absolute lymphocyte count (ALC) <25000 cells/mcL
  • Cohort 1A and 1C: at least 2 prior lines of systemic therapy for CLL/SLL
  • Cohort 1B: at least 1 prior line of therapy and is bruton tyrosine kinase inhibitor (BTKi)-sensitive; Substudy 2 Specific Inclusion Criteria:
  • MCL diagnosis per WHO
  • Clinical Stage II, III, or IV by Ann Arbor Classification
  • At least 1 measurable site per Lugano
  • ALC < 25000 cells/mcL
  • Cohort 2A and 2C: Relapse or progressed after 2 or more lines of therapy including BTKi; Substudy 3 Specific Inclusion Criteria:
  • At least 1 measurable site as per Lugano
  • Left ventricular ejection fraction (LVEF) ≥50%
  • Participant must be no older than 79 years of age at the time of signing ICF
  • Contraception at least 90 days after last dose of surovatamig or 4 months after last dose of vincristine, and 6 months after the last dose of cyclophosphamide, or doxorubicin
  • Cohort 3A:; Histologically confirmed diagnosis of previously untreated large B-cell Lymphoma (LBCL) per WHO 2022; R/R B-NHL after at least 1 prior lines of systemic therapy; International Prognostic Index (IPI) 2-5
  • Cohort 3B:; Histologically confirmed diagnosis of previously untreated large B-cell Lymphoma (LBCL) per WHO 2022; IPI score of 2 to 5

Who cannot take part

  • Surgery within 14 days of study drug
  • Unresolved Grade >2 AEs from prior anticancer therapy (except alopecia or fatigue)
  • Any systemic therapy within 5 half-lives or 21 days (whichever is shorter) prior to treatment
  • Radiation therapy within 28 days
  • Prior CAR T-cell therapy or autologous-haematopoietic stem cell transplant (HSCT) within 12 weeks or prior T-cell engager (TCE) within 8 weeks
  • Prior Grade > 3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) event
  • Prior allogeneic HSCT or solid organ transplantation within 24 weeks of starting Cycle 1 Day 1
  • Cohort 1B: bleeding diathesis, CYP3A inhibitor or inducer, history of ICH or stroke within 24 weeks, GI malabsorption, receiving vitamin K antagonist; Substudy 3 Specific Exclusion Criteria:
  • Clinically significant cardiovascular (CV) disease
  • Active, significant, uncontrolled infection or autoimmune disease requiring systemic therapy including participants with known history of haemophagocytic lymphohistiocytosis (HLH); Substudy 1 Specific Exclusion Criteria:
  • Master Exclusion Criteria applicable to all substudies:
  • Central nervous system (CNS) lymphoma
  • CLL/SLL transformation to more aggressive form of lymphoma
  • Mediastinal grey-zone lymphoma, Burkitt, Richter's transformation, primary effusion large B-cell lymphoma (LBCL)
  • Cumulative dose of anthracycline >150 mg/m2

Where in United States

Also in 12 other countries, 47 sites

  • Boston, MassachusettsHospital not named in the registryTaking people
  • Charlotte, North CarolinaHospital not named in the registryTaking people
  • Columbus, OhioHospital not named in the registryTaking people
  • Hackensack, New JerseyHospital not named in the registryTaking people
  • Houston, TexasHospital not named in the registryNot yet recruiting
  • New Brunswick, New JerseyHospital not named in the registryTaking people
  • New YorkHospital not named in the registryTaking people
  • Philadelphia, PennsylvaniaHospital not named in the registryTaking people
  • Pittsburgh, PennsylvaniaHospital not named in the registryTaking people
  • Portland, OregonHospital not named in the registryTaking people
  • Providence, Rhode IslandHospital not named in the registryTaking people
  • Winston-Salem, North CarolinaHospital not named in the registryNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies

The 7 groups in the trial

  • Substudy 1 (RR CLL/SLL): Cohort 1A (Surovatamig Monotherapy)Treatment being tested

    Participants will receive surovatamig monotherapy as subcutaneous (SC) injection.

    Treatment: Surovatamig

  • Substudy 1 (RR CLL/SLL): Cohort 1B (Surovatamig + Acalabrutinib)Treatment being tested

    Participants will receive surovatamig as SC injection. Participants will receive acalabrutinib tablet orally twice daily.

    Treatment: Surovatamig and Acalabrutinib

  • Substudy 1 (RR CLL/SLL): Cohort 1C (Surovatamig Monotherapy)Treatment being tested

    Participants will receive surovatamig monotherapy as intravenous (IV) infusion.

    Treatment: Surovatamig

  • Substudy 2 (RR MCL): Cohort 2A (Surovatamig Monotherapy)Treatment being tested

    Participants will receive surovatamig monotherapy as SC injection.

    Treatment: Surovatamig

  • Substudy 2 (RR MCL): Cohort 2C (Surovatamig Monotherapy)Treatment being tested

    Participants will receive surovatamig monotherapy as IV infusion.

    Treatment: Surovatamig

  • Substudy 3 (LBCL): Cohort 3A 2SUD (Surovatamig + RCHOP)Treatment being tested

    Participants will receive surovatamig as IV infusion with a 2SUD (double step-up dosing) schedule for priming in combination with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.

    Treatment: Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine, and Doxorubicin

  • Substudy 3 (LBCL): Cohort 3B 3SUD (Surovatamig + RCHOP)Treatment being tested

    Participants will receive surovatamig as IV infusion with a 3SUD (triple step-up dosing) schedule for priming in combination with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.

    Treatment: Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine, and Doxorubicin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies
Plain-language title
Tests surovatamig alone or with other drugs in B-cell blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
28 October 2026